ClinicalTrials.gg
CompletedNCT04091646Updated Jul 3, 2023Results posted

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

A Phase 2 interventional study of Roflumilast Foam 0.3% and Vehicle foam in Seborrheic Dermatitis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 24 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Dermatitis, Seborrheic with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Dermatitis, Seborrheic · United States.

Enrollment
4th of 18
226 · median 62
Started
2019
with 1 other
Phase 2
9 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
3 of 19
Arcutis Biotherapeutics, Inc.

Among the 19 studies in Dermatitis, Seborrheic with a site in United States, this one is the 4th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 13th registered.

Dermatitis, Seborrheic

58 studies on the registry are indexed under Dermatitis, Seborrheic; 7 are open to participants now.

Browse Dermatitis, Seborrheic studies →

Open to participants now

1 of the 19 studies in Dermatitis, Seborrheic with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Dermatitis, Seborrheic studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Dermatitis, Seborrheic with a site in United States, or all of them as a file.
02

Study summary

This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis.

03

Conditions studied

  • Seborrheic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants legally competent to sign and give .
  2. Males and females ages 18 years and older (inclusive) at the time of consent.
  3. Clinical diagnosis of seborrheic dermatitis of at least 3 months duration as determined by the Investigator. Stable disease for the past 4 weeks.
  4. Seborrheic dermatitis of the scalp and/or face and/or trunk and/or intertriginous areas.
  5. An Investigator Global Assessment (IGA) of disease severity of at least Moderate ('3') at Baseline.
  6. Overall Assessment of Erythema and Overall Assessment of Scaling scores of at least Moderate ('2') at Baseline.
  7. Females of (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2).
  8. Females of non-childbearing potential must either be with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization.
  9. Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.
  10. Subjects are considered reliable and capable of adhering to the Protocol and visit schedule according to the Investigator judgment.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic dermatitis prior to the Baseline visit and during the study according to Excluded Medications and Treatments.
  2. Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
  3. Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin for two weeks prior to the Baseline visit (Visit 2) and during the study.
  4. Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, , barbiturates (including phenobarbital), phenytoin, rifampin, and carbamazepine for two weeks prior to the Baseline visit (Visit 2) and during the study.
  5. Subjects with PHQ-8 ≥10 at Screening or Baseline visits.
  6. Previous treatment with ARQ-151 and ARQ-154.
  7. Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE-4 inhibitors (apremilast) within the past 4 weeks.
  8. Known allergies to in ARQ-154 foam.
  9. Known or suspected: severe renal insufficiency or moderate to severe hepatic disorders; to component(s) of the products; or history of severe depression, suicidal ideation, or Baseline/Screening C-SSRS indicative of suicidal ideation, whether lifetime or recent/current.
  10. Subjects with a history of a major surgery within 8 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.
  11. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
  12. Subjects unable to apply product to the scalp due to physical limitations.
  13. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  14. A history of abuse of alcohol or other drugs, at the discretion of the Investigator.
  15. Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
  16. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects.
  17. Any condition that in the Investigator's assessment would preclude the subject from participating in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
226 participants (actual)

Study arms

  • Active comparator
    Roflumilast Foam 0.3%

    Participants apply roflumilast foam 0.3% once daily (QD) to all areas of seborrheic dermatitis once daily for 8 weeks.

    Drug: Roflumilast Foam 0.3%

  • Placebo comparator
    Vehicle Foam

    Participants apply inactive vehicle foam matched to roflumilast foam QD for 8 weeks.

    Drug: Vehicle foam

Interventions

  • Roflumilast foam for topical application.

    Also known as: ARQ-154

  • DrugVehicle foam

    Vehicle foam for topical application.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Achievement of Investigator Global Assessment (IGA) Success at Week 8

    The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.

    Time frame: Week 8

Secondary outcomes

  1. Achievement of IGA Success at Weeks 2 and 4

    The number of participants achieving "success" in IGA assessment of disease severity at Weeks 2 and 4 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.

    Time frame: Weeks 2 and 4

  2. Change From Baseline in Overall Assessment of Erythema Score

    The mean (SD) change from baseline in Overall Assessment of Erythema score at Weeks 2, 4, and 8 is shown. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.

    Time frame: Weeks 2, 4, and 8

  3. Achievement of Overall Assessment of Erythema Success

    The number of participants achieving "success" in Overall Assessment of Erythema at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an overall score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Erythema is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.

    Time frame: Weeks 2, 4, and 8

  4. Change From Baseline in Overall Assessment of Scaling Score

    The mean (SD) change from baseline in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is shown. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.

    Time frame: Weeks 2, 4, and 8

  5. Achievement of Overall Assessment of Scaling Success

    The number of participants achieving "success" in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an Overall Assessment of Scaling score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.

    Time frame: Weeks 2, 4, and 8

  6. Change From Baseline in Worst Itch Numeric Rating Scale (WI-NRS) Score

    The change from baseline in WI-NRS is shown. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Negative values represent a decrease in worst itch from baseline, and positive values indicate an increase.

    Time frame: Weeks 2, 4, and 8

  7. Achievement of WI-NRS Success

    The number of participants achieving WI-NRS "success" at Weeks 2, 4, and 8 is presented. Success was defined as achievement of a ≥4-point improvement from baseline WI-NRS score. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.

    Time frame: Weeks 2, 4, and 8

07

Results

Posted Jul 3, 2023

Participant flow

Participant flow — Overall Study
MilestoneRoflumilast Foam 0.3%Vehicle Foam
Started15472
Completed14167
Not completed135
Withdrew: Adverse event21
Withdrew: Lost to follow-up62
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject41
Withdrew: Participant incarcerated10

Outcome measures

PrimaryAchievement of Investigator Global Assessment (IGA) Success at Week 8

The number of participants achieving "success" in IGA assessment of disease severity at Week 8 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Achievement of Investigator Global Assessment (IGA) Success at Week 8
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Investigator Global Assessment (IGA) Success at Week 810427
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.95 · 95% CI 2.51 to 9.76Common OR stratified by pooled study site and baseline IGA per randomization with multiple imputation of missing data.
SecondaryAchievement of IGA Success at Weeks 2 and 4

The number of participants achieving "success" in IGA assessment of disease severity at Weeks 2 and 4 is presented for each arm. Success was defined as achievement of an IGA score of 0 ('completely clear') or 1 ('almost clear'), accompanied by a ≥2-grade improvement from baseline IGA score. The IGA is 5-point scale assessing the severity of Seborrheic Dermatitis, with scores ranging from 0 ('completely clear') to 4 ('severe'), and higher scores indicate greater severity. The IGA scores are based on observed data, whereas odds ratio and p-values were calculated using multiple imputation of missing values.

Time frame:
Weeks 2 and 4
Reported as:
Count of participants · Participants
Achievement of IGA Success at Weeks 2 and 4
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Week 25110
Week 48119
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0033 · Odds ratio (or): 3.31 · 95% CI 1.46 to 7.52Common OR stratified by pooled study site and baseline IGA per randomization with multiple imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 3.78 · 95% CI 1.94 to 7.38Common OR stratified by pooled study site and baseline IGA per randomization with multiple imputation of missing data.
SecondaryChange From Baseline in Overall Assessment of Erythema Score

The mean (SD) change from baseline in Overall Assessment of Erythema score at Weeks 2, 4, and 8 is shown. The Erythema Assessment is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
Change From Baseline in Overall Assessment of Erythema Score
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Week 2-1.0 ± 0.73-0.4 ± 0.65
Week 4-1.3 ± 0.73-0.7 ± 0.68
Week 8-1.4 ± 0.78-0.8 ± 0.85
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Roflumilast Foam 0.3% vs Vehicle Foam · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Roflumilast Foam 0.3% vs Vehicle Foam · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryAchievement of Overall Assessment of Erythema Success

The number of participants achieving "success" in Overall Assessment of Erythema at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an overall score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Erythema is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("None: no evidence of erythema.") to 3 ("Severe: Intense \[fiery red\] erythema."). Higher scores indicate greater severity.

Time frame:
Weeks 2, 4, and 8
Reported as:
Count of participants · Participants
Achievement of Overall Assessment of Erythema Success
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Week 2344
Week 4517
Week 86314
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0065 · Odds ratio (or): 5.05 · 95% CI 1.49 to 17.13Stratification by pooled study site and baseline IGA per randomization with no imputation of missing data
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 5.36 · 95% CI 2.15 to 13.38Stratification by pooled study site and baseline IGA per randomization with no imputation of missing data
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0021 · Odds ratio (or): 3.15 · 95% CI 1.50 to 6.63Stratification by pooled study site and baseline IGA per randomization with no imputation of missing data
SecondaryChange From Baseline in Overall Assessment of Scaling Score

The mean (SD) change from baseline in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is shown. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · Score on a scale
Change From Baseline in Overall Assessment of Scaling Score
Score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Week 2-1.0 ± 0.77-0.6 ± 0.78
Week 4-1.3 ± 0.76-0.8 ± 0.81
Week 8-1.5 ± 0.75-1.0 ± 0.83
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Roflumilast Foam 0.3% vs Vehicle Foam · Wilcoxon (Mann-Whitney) · p = <0.0001
  • Roflumilast Foam 0.3% vs Vehicle Foam · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryAchievement of Overall Assessment of Scaling Success

The number of participants achieving "success" in Overall Assessment of Scaling score at Weeks 2, 4, and 8 is presented for each arm. Success was defined as achievement of an Overall Assessment of Scaling score of 0 or 1 plus a ≥2 grade improvement from Baseline. The Overall Assessment of Scaling is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("No scaling: No scaling evident on lesions.") to 3 ("Severe: Coarse, thick scales, with flaking into clothes or skin."). Higher scores indicate greater severity.

Time frame:
Weeks 2, 4, and 8
Reported as:
Count of participants · Participants
Achievement of Overall Assessment of Scaling Success
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Week 24010
Week 45914
Week 86314
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0759 · Odds ratio (or): 1.98 · 95% CI 0.90 to 4.33Common OR stratified by pooled study site and baseline IGA per randomization with no imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0122 · Odds ratio (or): 2.33 · 95% CI 1.18 to 4.61Common OR stratified by pooled study site and baseline IGA per randomization with no imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0003 · Odds ratio (or): 3.37 · 95% CI 1.74 to 6.55Common OR stratified by pooled study site and baseline IGA per randomization with no imputation of missing data.
SecondaryChange From Baseline in Worst Itch Numeric Rating Scale (WI-NRS) Score

The change from baseline in WI-NRS is shown. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. Negative values represent a decrease in worst itch from baseline, and positive values indicate an increase.

Time frame:
Weeks 2, 4, and 8
Reported as:
Mean · score on a scale
Change From Baseline in Worst Itch Numeric Rating Scale (WI-NRS) Score
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Week 2-3.0 ± 2.80-1.7 ± 2.08
Week 4-3.5 ± 2.72-1.9 ± 2.22
Week 8-3.7 ± 2.83-2.0 ± 2.37
SecondaryAchievement of WI-NRS Success

The number of participants achieving WI-NRS "success" at Weeks 2, 4, and 8 is presented. Success was defined as achievement of a ≥4-point improvement from baseline WI-NRS score. The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.

Time frame:
Weeks 2, 4, and 8
Reported as:
Count of participants · Participants
Achievement of WI-NRS Success
ParticipantsRoflumilast Foam 0.3%Vehicle Foam
Week 26513
Week 47015
Week 87318
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0007 · Odds ratio (or): 3.62 · 95% CI 1.72 to 7.63Common OR stratified by pooled study site and baseline IGA per randomization with no imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0009 · Odds ratio (or): 3.30 · 95% CI 1.63 to 6.68Common OR stratified by pooled study site and baseline IGA per randomization with no imputation of missing data.
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0007 · Odds ratio (or): 3.19 · 95% CI 1.60 to 6.35Common OR stratified by pooled study site and baseline IGA per randomization with no imputation of missing data.

Adverse events

Collected over Up to ~63 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Foam 0.3%0/154 (0%)0/154 (0%)0/154 (0%)
Vehicle Foam0/72 (0%)0/72 (0%)0/72 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Foam 0.3%Vehicle FoamTotal
Mean45.3 ± 17.0144.2 ± 16.2744.9 ± 16.75
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Female7832110
Male7640116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Hispanic or Latino291645
Not Hispanic or Latino12556181
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
American-Indian or Alaska Native101
Asian718
Black or African-American17623
Native Hawaiian or Other Pacific Islander000
White12362185
Other123
More than One Race516
Investigator Global Assessment (IGA) Baseline Score
Investigator Global Assessment (IGA) Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
0 Completely Clear000
1 Almost Clear000
2 Mild000
3 Moderate14169210
4 Severe13316
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score
Worst Itch Numerical Rating Scale (WI-NRS) Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
0729
1628
29514
37411
418826
5131124
620525
7271744
8241640
914014
109211
Overall Assessment of Erythema Baseline Score
Overall Assessment of Erythema Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
None000
Mild000
Moderate13566201
Severe19625
Overall Assessment of Scaling Baseline Score
Overall Assessment of Scaling Baseline Score(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
None000
Mild000
Moderate13058188
Severe241438
08

Study locations

24 sites
  • Arcutis Biotherapeutics Clinical Site 19
    Fremont, California 94538, United States
  • Arcutis Biotherapeutics Clinical Site 21
    Santa Monica, California 90404, United States
  • Arcutis Biotherapeutics Clinical Site 42
    Coral Gables, Florida 33134, United States
  • Arcutis Biotherapeutics Clinical Site 24
    Miami, Florida 33144, United States
  • Arcutis Biotherapeutics Clinical Site 12
    Tampa, Florida 33613, United States
  • Arcutis Biotherapeutics Clinical Site 10
    Rolling Meadows, Illinois 60008, United States
  • Arcutis Biotherapeutics Clinical Site 22
    Plainfield, Indiana 46168, United States
  • Arcutis Biotherapeutics Clinical Site 15
    Louisville, Kentucky 40217, United States
  • Arcutis Biotherapeutics Clinical Site 28
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 40
    Clinton Township, Michigan 48038, United States
  • Arcutis Biotherapeutics Clinical Site 20
    Detroit, Michigan 48202, United States
  • Arcutis Biotherapeutics Clinical Site 14
    Fridley, Minnesota 55432, United States
  • Arcutis Biotherapeutics Clinical Site 23
    High Point, North Carolina 27262, United States
  • Arcutis Biotherapeutics Clinical Site 18
    Bexley, Ohio 43209, United States
  • Arcutis Biotherapeutics Clinical Site 29
    Portland, Oregon 97210, United States
  • Arcutis Biotherapeutics Clinical Site 27
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Biotherapeutics Clinical Site 13
    Arlington, Texas 76011, United States
  • Arcutis Biotherapeutics Clinical Site 11
    Austin, Texas 78759, United States
  • Arcutis Biotherapeutics Clinical Site 41
    College Station, Texas 77845, United States
  • Arcutis Biotherapeutics Clinical Site 25
    Houston, Texas 77056, United States
  • Arcutis Biotherapeutics Clinical Site 26
    Pflugerville, Texas 78660, United States
  • Arcutis Biotherapeutics Clinical Site 17
    Norfolk, Virginia 23502, United States
  • Arcutis Biotherapeutics Clinical Site 31
    Markham, Ontario L3P 1X2, Canada
  • Arcutis Biotherapeutics Clinical Site 30
    Windsor, Ontario N8W 1E6, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Aug 2020, 8 months.

Results were first posted in Jul 2023, 2 years 10 months after primary completion. A results delay was requested in Jun 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2019
First posted
Sep 17, 2019
StartActual
Dec 4, 2019
Primary completionActual
Aug 18, 2020
CompletionActual
Aug 21, 2020
Results delay requested
Jun 18, 2021
Results first posted
Jul 3, 2023
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04091646
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Dec 4, 2019
Primary completion
Aug 18, 2020
Completion
Aug 21, 2020
Results posted
Jul 3, 2023
Last update
Jul 3, 2023

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ARQ-154

Start the discussion